A Study to Evaluate the Efficacy, Safety, and Tolerability of BMS-986278 in Participants with Idiopathic Pulmonary Fibrosis

This trial will randomly assign idiopathic pulmonary fibrosis (IPF) patients to twice daily BMS-986278 at 2 different doses versus placebo.

The goal is to study the safety and efficacy of BMS-986278 in improving lung function of IPF patients over 52 weeks.

In order to participate you must meet the following criteria: 

• Have with IPF and are ≥ 40 years of age at the time of signing the informed consent.
• Have a diagnosis of IPF within 7 years prior to screening that is supported by centrally read chest high-resolution computed tomography (HRCT) obtained at screening and verification of usual interstitial pneumonia. 
• If on pirfenidone or nintedanib, participants must have been on a stable dose for at least 90 days prior to screening. 
• If not currently on pirfenidone or nintedanib, participants must not have received either of these medications within 28 days prior to screening.

This is a partial list of eligibility requirements. To inquire about your eligibility, please call the contact number provided. If you wish to inquire via email, please include the title of the study in your message.